MYC-Dependent Upregulation of the De Novo Serine and Glycine Synthesis Pathway is a Targetable Metabolic Vulnerability in Group 3 Medulloblastoma

Medicine, Neurology, Neurosurgery, Oncology,
medulloblastoma   MYC amplification   metabolic vulnerability   serine synthesis   glycine synthesis   PHGDH inhibition   therapeutic strategy  

Targeting the Serine/Glycine Synthesis Pathway in MYC-Driven Medulloblastoma Background Medulloblastoma is one of the most common malignant brain tumors in children, accounting for a significant proportion of childhood cancer deaths. Based on molecular characteristics, medulloblastoma is classified into four major subgroups: WNT, SHH, Group 3 (MBGr...

Mapping Tumor Habitats in Isocitrate Dehydrogenase-Wild Type Glioblastoma: Integrating MRI, Pathologic, and RNA Data

Medicine, Neurology, Medical Imaging, Oncology,
glioblastoma   tumor habitats   MRI   pathology   RNA sequencing   spatial heterogeneity   IDH-wild type  

Pathological Validation of MRI Tumor Habitats in Glioblastoma Background Introduction Glioblastoma (GBM) is a highly malignant brain tumor characterized by significant heterogeneity and invasiveness. Due to its complex tumor microenvironment (TME), traditional imaging methods struggle to accurately distinguish different tumor regions, such as the t...

Long-term Outcome of the Milano-Hyperfractionated Accelerated Radiotherapy Strategy for High-Risk Medulloblastoma, Including the Impact of Molecular Subtype

Medicine, Neurology, Neurosurgery, Oncology,
high-risk medulloblastoma   hyperfractionated accelerated radiotherapy   molecular subtype   chemotherapy response   long-term survival  

Long-Term Outcomes of High-Risk Medulloblastoma Treatment Background Medulloblastoma is one of the most common malignant brain tumors in children. Despite advancements in treatment, the prognosis for high-risk medulloblastoma patients remains poor. High-risk medulloblastoma typically includes patients with metastatic disease, TP53 mutations, MYC/MY...

Molecular and Clinical Heterogeneity within MYC-Family Amplified Medulloblastoma is Associated with Survival Outcomes: A Multicenter Cohort Study

Medicine, Neurology, Neurosurgery, Oncology,
medulloblastoma   MYC amplification   clinical heterogeneity   molecular subgroups   survival outcomes   high-risk disease   treatment strategies  

Clinical and Biological Heterogeneity in MYC/MYCN-Amplified Medulloblastoma Academic Background Medulloblastoma (MB) is one of the most common malignant brain tumors in children. Despite recent advances in treatment, approximately 30% of patients still die from the disease, and survivors often face long-term treatment-related complications. Amplifi...

Distinct Relapse Patterns Across Molecular Ependymoma Types

Distinct Relapse Patterns Across Molecular Ependymoma Types

Medicine, Neurology, Neurosurgery, Oncology,
ependymoma   relapse patterns   molecular types   intracranial tumors   clinical research  

Study on Relapse Patterns of Intracranial Ependymoma Background Ependymoma (EPn) is a rare but highly heterogeneous central nervous system tumor, particularly common in children. Despite significant advances in the biology and molecular characteristics of ependymoma in recent years, its relapse patterns remain unclear. The timing and location of re...

Determining Risk Features for Medulloblastoma in the Molecular Era

Medicine, Pediatrics, Neurology, Oncology,
medulloblastoma   molecular classification   risk stratification   radiation therapy   methylation profiling   chemotherapy   survival rate  

Advances in Risk Stratification and Treatment Strategies for Medulloblastoma Background Medulloblastoma is a common malignant brain tumor in children, with significant differences in treatment and prognosis depending on its molecular subtypes. In recent years, advances in molecular biology have revealed that medulloblastoma can be further divided i...